An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
This study is currently recruiting participants.
Verified March 2013 by to-BBB technologies B.V.
Sponsor:
to-BBB technologies B.V.
Information provided by (Responsible Party):
to-BBB technologies B.V.
ClinicalTrials.gov Identifier:
NCT01386580
First received: June 28, 2011
Last updated: March 6, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |